Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ: CGON )

32.90 -2.60 (-7.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 754,729
Open 35.83
Bid (Size) 32.10 (1)
Ask (Size) 34.23 (1)
Prev. Close 35.50
Today's Range 32.53 - 35.83
52wk Range 25.77 - 50.23
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire

Performance

YTD
-17.04%
-17.04%
1 Month
-9.73%
-9.73%
3 Month
-8.83%
-8.83%
6 Month
+10.65%
+10.65%
1 Year
-17.04%
-17.04%

More News

Read More
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
A Closer Look at 9 Analyst Recommendations For CG Oncology
Via Benzinga
Decoding 10 Analyst Evaluations For CG Oncology
Via Benzinga
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
Via InvestorPlace
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
Via InvestorPlace
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
Via Benzinga
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
From CG Oncology Inc.
Via GlobeNewswire
IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.